Five Prime ends antibody deal with Inhibrx

Five Prime Therapeutics Inc. (NASDAQ:FPRX) said it will terminate a 2015 deal with Inhibrx LLC (La Jolla, Calif.) to develop and commercialize Inhibrx’s preclinical glucocorticoid-induced tumor necrosis factor receptor (TNFR)-related protein (GITR; TNFRSF18) antibody program. Five Prime COO Aron Knickerbocker told BioCentury the termination was due to pipeline prioritization and the "crowded, competitive landscape" around GITR. The termination will be effective Dec. 27...